Filed Under:Health Insurance, Individual Health

PwC Survey: Drug Manufacturers Must Demonstrate Clinical, Economic Benefits of Products

Photo credit: vichie81
Photo credit: vichie81

A shift in consumer and provider preferences could hurt revenues for drug manufacturers that don’t speed efforts to demonstrate the clinical and economic benefits of their products, according to a new PricewaterhouseCoopers survey.

PwC, London, U.K., published this finding in a survey that explores how well health insurers and pharmaceutical companies work together using information about drug effectiveness in the care of patients. The phone survey of executives at 100 different health insurers uncovered the following:

• To be considered for drug formulary placement, 82% of health plans say a drug manufacturer must demonstrate a clear clinical benefit compared with current branded and generic treatments, and 78% demand clear proof of cost savings.

• 75% of insurers characterize their relationship with pharmaceutical companies as transactional vs. collaborative. • 44% said they aren’t at all confident in the data provided by the drug industry • 16% of health insurers have adopted new payment and contracting arrangements such as outcomes-based payments, risk-sharing agreements and bundled payments with pharmaceutical companies. Of those that haven’t, 37% expect to adopt them within the next three years.

• Only five percent of health insurers are very confident—and 44 percent aren’t at all confident—in the economic data provided by the drug industry when making coverage and formulary decisions.  Only seven percent are very confident in the information to evaluate a drug’s comparative effectiveness.   • More than half (52%) of insurers rely on independent data to evaluate drug effectiveness.  The three most influential factors health plans use when making formulary decisions are:  the availability of a generic equivalent, physicians’ opinions and regulatory guidance. • Sixteen percent of health insurers have adopted new payment and contracting arrangements such as outcomes-based payments, risk-sharing agreements and bundled payments with pharmaceutical companies.  Of those that haven’t, 37 percent expect to adopt them within the next three years. View the full report here.

Featured Video

Most Recent Videos

Behind the scenes with Vicki Gunvalson [VIDEO]

Provided by LIFEHEALTHPRO

In this exclusive interview, Vicki Gunvalson shares how she built a $15 million a year annuity business by planning for...

Regulator: Market may need to reinvent LTCI

Provided by LIFEHEALTHPRO

Cioppa says Maine's governor wants to spur the creation of better products.

Dementia: It's more than Alzheimer's

Provided by LIFEHEALTHPRO

An association calls for policymakers to remember lesser-known neurodegenerative conditions.

Protesters Disrupt WellPoint Annual Meeting

Provided by LIFEHEALTHPRO

Hecklers call for more disclosures of information about political contributions.

Related resources

More Resources

Comments

Power your business with up-to-the-minute insurance news, analysis, and best practices from LifeHealthPro Daily eNewsletter – FREE.

Power your business with LifeHealthPro Daily eNewsletter – FREE.

Enter a valid email address.
Close
Nichole Morford

Nichole Morford
Managing Editor

Thank you for subscribing to LifeHealthPro Daily!

Check Out More eNewsletters Now! Close

Advertisement. Closing in 15 seconds.